Latest Headlines

  1. Merck KGaA Targets Chinese Market, Builds New Shanghai Manufacturing Facility
    7/29/2014

    Merck KGaA announced in a press release that it is strengthening its commitment to the Chinese market as part of its overall strategy to target emerging markets.

  2. Hikma Acquires Ben Venue Generic Injectables Manufacturing Facility In Ohio
    7/29/2014

    Hikma Pharmaceuticals PLC announced in a press release that it has acquired the Ben Venue Laboratories manufacturing facility in Bedford, OH. Ben Venue is part of Boehringer Ingelheim, and its generic injectables manufacturing site includes four manufacturing plants and a Quality and Development Centre (QDC).

  3. EU And Pharma Industry Debate Off-Label Use of Meds
    7/29/2014

    In order to cut national healthcare bills, cash-strapped European governments want to reimburse patients who use drugs that aren’t approved for their particular conditions. However, pharmaceutical companies aren’t too keen about this, arguing that prescribing medicines for so-called off-label use could not only harm patients, but also break EU law.

  4. Attend The PDA Europe Workshop On Container Closure Integrity Testing
    7/29/2014

    Announcing an upcoming PDA Workshop on Container Closure Integrity Testing, November 6-7, 2014 at the Rama-da Hotel Messe in Munich, Germany.

  5. DRG Lauds Evolocumab As The Gold-Standard Among PCSK9 Inhibitors
    7/28/2014
    A report from the Decision Resources Group gives the gold medal to Amgen’s evolocumab in the race among statin add-on therapies for dyslipidemia in its report Dyslipidemia (in statin-treated patients): Do Physicians Have High Hopes for LDL-lowering Therapies in Cardiovascular Outcomes?
  6. What You Missed From The FDA Last Week—July 21-25, 2014
    7/28/2014

    Novartis’ company Sandoz announced that the FDA has accepted its Biologics License Application (BLA) for the biosimilar filgrastim. The biosimilar is designed to decrease the incidence of infection in patients with nonmyeloid malignancies that have been treated with myelosuppressive anticancer drugs. Filgrastim has been marketed under the brand name Zarzio in 40 countries outside of the U.S. and is the most popular G-CSF in Europe.

  7. Stallergenes Acquires Alergo Pharma, Enlarges Latin American Reach
    7/25/2014

    Allergies specialist global healthcare company Stallergenes announced that it has completed an acquisition of the entire share capital of Argentinean allergen immunotherapy (AIT) firm, Alergo Pharma. No financial terms of the agreement were disclosed by either company.

  8. Lupin, Other U.S. Firms Consider Bid For GSK Generics
    7/25/2014

    Inside sources reveal that Indian pharmaceutical generics firm Lupin, along with other U.S. pharma firms, is considering bidding for GlaxoSmithKline’s auctioned mature and generic drugs.

  9. FDA Recalls All Non-Expired Sterile Drugs From Unique Pharma
    7/25/2014

    The U.S. Food and Drug Administration (FDA) announced that it is issuing a voluntary, nationwide recall of all non-expired, supposedly sterile drugs produced and distributed by Unique Pharmaceuticals.

  10. BMS And Ono Enter Immuno-Oncology Partnership In Asia
    7/25/2014

    Bristol-Myers Squibb and Ono Pharmaceuticals announced that the companies have entered an agreement to develop and market Opdivo (nivolumab), Yervoy (ipilimumab), and three other drugs in South East Asia. Ono originally held exclusive rights to nivolumab in the three countries while BMS retained rights in the rest of its territories. The new agreement provides BMS access to Opdivo in the three countries. BMS also held global rights to Yervoy and the three other drugs, namely lirilumab, urelumab, and BMS-986016.

Newsletter Signup
Newsletter Signup